[Evaluation of immunoreactivity to erbB-2 protein as a marker of prognosis in bile duct carcinoma].
Recent studies of erbB-2 expression have shown that the erbB-2 oncoprotein correlated with poor prognosis of patients with breast cancer. Surgical treatment of the bile duct carcinoma is currently unsatisfactory. To evaluate erbB-2 oncoprotein as a marker of prognosis, we analyzed 68 bile duct carcinomas immunohistologically, using monoclonal antibody against erbB-2 oncoprotein, as well as clinicopathological data and outcome. High incidence of expression of erbB-2 oncoprotein was shown in bile duct carcinoma. Positive rates of erbB-2 oncoprotein correlated with stage of bile duct carcinoma. Survival of patients with erbB-2 expression cancer was shorter than those without erbB-2 expression cancer and erbB-2 expression has a prognostic value in bile duct carcinoma.
Second Department of Surgery, Nagasaki University School of Medicine, Japan.
K
K
Motojima
K
K
Komuta
A
A
Hiasa
T
T
Tsuribune
T
T
Hashimoto
T
T
Tsunoda
T
T
Kanematsu
D001650:Bile Duct Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis* / Q000276:immunology; D018719:Erb-b2 Receptor Tyrosine Kinases
D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases